|
1
|
Friedlander M, Trimble E, Tinker A,
Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, et al: Clinical trials in recurrent
ovarian cancer. Int J Gynecol Cancer. 21:771–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kyrgiou M, Salanti G, Pavlidis N,
Paraskevaidis E and Ioannidis JP: Survival benefits with diverse
chemotherapy regimens for ovarian cancer: Meta-analysis of multiple
treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rowley M, Grothey E and Couch FJ: The role
of Tbx2 and Tbx3 in mammary development and tumorigenesis. J
Mammary Gland Biol Neoplasia. 9:109–118. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abrahams A, Parker MI and Prince S: The
T-box transcription factor Tbx2: Its role in development and
possible implication in cancer. IUBMB Life. 62:92–102.
2010.PubMed/NCBI
|
|
6
|
Peres J, Davis E, Mowla S, Bennett DC, Li
JA, Wansleben S and Prince S: The highly homologous T-Box
transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jacobs JJ, Keblusek P, Robanus-Maandag E,
Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ,
Koh EY, Daley GQ and van Lohuizen M: Senescence bypass screen
identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified
in a subset of human breast cancers. Nat Genet. 26:291–299. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vance KW, Carreira S, Brosch G and Goding
CR: Tbx2 is overexpressed and plays an important role in
maintaining proliferation and suppression of senescence in
melanomas. Cancer Res. 65:2260–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taneja P, Maglic D, Kai F, Zhu S, Kendig
RD, Fry EA and Inoue K: Classical and novel prognostic markers for
breast cancer and their clinical significance. Clin Med Insights
Oncol. 4:15–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mahlamäki EH, Bärlund M, Tanner M,
Gorunova L, Höglund M, Karhu R and Kallioniemi A: Frequent
amplification of 8q24, 11q, 17q and 20q-specific genes in
pancreatic cancer. Genes Chromosomes Cancer. 35:353–358. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu H, Liu BO, Liu A, Li K and Zhao H:
T-box 2 expression predicts poor prognosis in gastric cancer. Oncol
Lett. 10:1689–1693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nandana S, Tripathi M, Duan P, Chu CY,
Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, et
al: Bone metastasis of prostate cancer can be therapeutically
targeted at the TBX2-WNT signaling axis. Cancer Res. 77:1331–1344.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang Y, Li Z, Zhong Q, Li G, Zhang Y and
Huang Z: Association of TBX2 and P21 expression with
clinicopathological features and survival of laryngeal squamous
cell carcinoma. Int J Clin Exp Med. 7:5394–5402. 2014.PubMed/NCBI
|
|
14
|
Zhang Z and Guo Y: High TBX2 expression
predicts poor prognosis in non-small cell lung cancer. Neoplasma.
61:476–480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davis E, Teng H, Bilican B, Parker MI, Liu
B, Carriera S, Goding CR and Prince S: Ectopic Tbx2 expression
results in polyploidy and cisplatin resistance. Oncogene.
27:976–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ismail A and Bateman A: Expression of TBX2
promotes anchorage-independent growth and survival in the
p53-negative SW13 adrenocortical carcinoma. Cancer Lett.
278:230–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
18
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dimova I, Orsetti B, Negre V, Rouge C,
Ursule L, Lasorsa L, Dimitrov R, Doganov N, Toncheva D and Theillet
C: Genomic markers for ovarian cancer at chromosomes 1, 8 and 17
revealed by array CGH analysis. Tumori. 95:357–366. 2009.PubMed/NCBI
|
|
20
|
Redmond KL, Crawford NT, Farmer H, D'Costa
ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP and
Mullan PB: T-box 2 represses NDRG1 through an EGR1-dependent
mechanism to drive the proliferation of breast cancer cells.
Oncogene. 29:3252–3262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sinclair CS, Adem C, Naderi A, Soderberg
CL, Johnson M, Wu K, Wadum L, Couch VL, Sellers TA, Schaid D, et
al: TBX2 is preferentially amplified in BRCA1- and BRCA2-related
breast tumors. Cancer Res. 62:3587–3591. 2002.PubMed/NCBI
|
|
22
|
Adem C, Soderberg CL, Hafner K, Reynolds
C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann
LC and Jenkins RB: ERBB2, TBX2, RPS6KB1 and MYC alterations in
breast tissues of BRCA1 and BRCA2 mutation carriers. Genes
Chromosomes Cancer. 41:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wansleben S, Davis E, Peres J and Prince
S: A novel role for the anti-senescence factor TBX2 in DNA repair
and cisplatin resistance. Cell Death Dis. 10:4:e8462013.
|
|
24
|
Demay F, Bilican B, Rodriguez M, Carreira
S, Pontecorvi M, Ling Y and Goding CR: T-box factors: Targeting to
chromatin and interaction with the histone H3 N-terminal tail.
Pigment Cell Res. 20:279–287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Warfel NA and El-Deiry WS: P21WAF1 and
tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang B, Lindley LE, Fernandez-Vega V,
Rieger ME, Sims AH and Briegel KJ: The T box transcription factor
TBX2 promotes epithelial-mesenchymal transition and invasion of
normal and malignant breast epithelial cells. PLoS One.
7:e413552012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu B, Zhang M, Williams EM, Keller C,
Mansoor A and Davie JK: TBX2 represses PTEN in rhabdomyosarcoma and
skeletal muscle. Oncogene. 35:4212–4224. 2016. View Article : Google Scholar : PubMed/NCBI
|
